Last reviewed · How we verify

NCT06237348

Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH

Completed NA Last updated 4 March 2025
What this trial tests

NA trial testing Simeox in Non-cystic Fibrosis Bronchiectasis in 50 participants. Completed in 30 December 2024.

Timeline
15 October 2023
Primary endpoint
30 December 2024
30 December 2024

Quick facts

Lead sponsorPhysio-Assist
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment50
Start date15 October 2023
Primary completion30 December 2024
Estimated completion30 December 2024
Sites2 locations across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Physio-Assist

Who can join

18 and older, any sex, with Non-cystic Fibrosis Bronchiectasis or Chronic Mucus Hypersecretion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot RCT will assess benefits of Simeox technology on lung function, respiratory symptoms, health-related quality of life, subjective efficiency, device adherence at home, Patient satisfaction, tolerance, safety, and telecare feasibility.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Simeox

Trials testing the same drug.

Other recruiting trials for Non-cystic Fibrosis Bronchiectasis

Currently open trials in the same condition.

Other Physio-Assist trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06237348.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing